PULMATRIX, INC. Patent applications |
Patent application number | Title | Published |
20150231066 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION - The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na | 08-20-2015 |
20150079173 | FORMULATIONS DECREASING PARTICLE EXHALATION - Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation. | 03-19-2015 |
20140134251 | PHARMACEUTICAL FORMULATIONS AND METHODS FOR TREATING RESPIRATORY TRACT INFECTIONS - The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca | 05-15-2014 |
20130281361 | METHODS OF TREATING AND PREVENTING RHINOVIRUS INFECTION - The present invention relates to methods of treating or preventing non-enveloped viral infection and/or disease caused by non-enveloped virus infection, particularly a viral infection caused by rhino virus. The methods comprise administering to an individual in need thereof an effective amount of a defensin peptide. The defensin peptide may be selected from α-, β-, or θ-defensins. | 10-24-2013 |
20130266653 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION - The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible. | 10-10-2013 |
20130243828 | CATIONIC DRY POWDERS - The invention relates to respirable dry particles that contain one or more divalent metal cations, such as calcium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent. | 09-19-2013 |
20130203715 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS - Methods are described for treating or preventing a respiratory infection by administering an effective amount of a TRP channel agonist. | 08-08-2013 |
20130164338 | TREATMENT OF CYSTIC FIBROSIS USING CALCIUM LACTATE, LEUCINE AND SODIUM CHLORIDE IN A RESPIRAPLE DRY POWDER - The invention relates to a methods for treating cystic fibrosis, comprising administering an effective amount of a calcium salt formulation to the respiratory tract of an individual with cystic fibrosis. The calcium salt formulation is can be a dry powder formulation. | 06-27-2013 |
20130149345 | RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE - The present invention relates to respirable dry powders that contain respirable dry particles that comprise about 20% (w/w) leucine, about 75% (w/w) calcium lactate, and about 5% (w/w) sodium chloride, or about 37.5% (w/w) leucine, about 58.6% (w/w) calcium lactate, and about 3.9% (w/w) sodium chloride, and methods for treating a subject using the respirable dry powders. | 06-13-2013 |
20130078282 | FORMULATIONS DECREASING PARTICLE EXHALATION - Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation. | 03-28-2013 |
20120107414 | PHARMACEUTICAL FORMULATIONS AND METHODS FOR TREATING RESPIRATORY TRACT INFECTIONS - The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca | 05-03-2012 |
20120070417 | ANTI-INFLUENZA FORMULATIONS AND METHODS - The invention relates to pharmaceutical compositions that contain a calcium salt as an active ingredient and also comprise another anti-influenza agent, and to methods for treating or preventing influenza virus infection. | 03-22-2012 |
20120064126 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES - The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection. | 03-15-2012 |
20120058198 | METHODS FOR TREATING AND PREVENTING PNEUMONIA AND VENTILATOR-ASSOCIATED TRACHEOBRONCHITIS - The invention relates to methods for treating bacterial infection of the respiratory tract, including pneumonias, such as ventilator-associated pneumonia, and to methods for treating ventilator-associated tracheobronchitis, comprising administering an effective amount of a salt formulation as an aerosol to the respiratory tract of an individual in need thereof. The formulations can also be used to reduce transmission of pathogen which can infect the respiratory tract, cause pneumonia or cause ventilator-associated tracheobronchitis. | 03-08-2012 |